ReviewOncogene2003
RAF antisense oligonucleotide as a tumor radiosensitizer.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Dabrafenib-Trametinib and Radiotherapy for OligoprogressiveBiomedicines · 2023Article
- Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity.Prostaglandins & other lipid mediators · 2019Review
- Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway.Experimental and therapeutic medicine · 2018Article
- Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).International journal of radiation oncology, biology, physics · 2016Review
- Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.Journal of neuro-oncology · 2016Article
- Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance.Scientific reports · 2015Article
- Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.Investigational new drugs · 2013Article
- Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.Hepatology research : the official journal of the Japan Society of Hepatology · 2013Article
- BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.Neoplasia (New York, N.Y.) · 2009Article
- Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Gene regulation and systems biology · 2008Article
- Selective Raf inhibition in cancer therapy.Expert opinion on therapeutic targets · 2007Review
- Signaling perturbations induced by invading H. pylori proteins in the host epithelial cells: a mathematical modeling approach.Journal of theoretical biology · 2007Article
- Raf kinases: function, regulation and role in human cancer.Biochimica et biophysica acta · 2007Review
- Antisense therapy in clinical oncology: preclinical and clinical experiences.Molecular biotechnology · 2006Review
- Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo.Cancer gene therapy · 2005Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The RAF-1 serine-threonine kinase plays a central role in signal transduction pathways involved in cell survival and proliferation. The concept of RAF-1-targeted disruption of cell signaling for therapeutic purposes was first advanced in 1989 with the demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous carcinoma cells transfected with a vector expressing antisense cDNA. However, the clinical application of antisense strategies has awaited the development of improved antisense oligonucleotide technologies and drug delivery methods. Nuclease-resistant phosphorothioated antisense oligonucleotides have been the focus of pharmaceutical industry attention. In vivo delivery of nuclease-sensitive, natural backbone/phosphodiester oligonucleotides has remained a formidable challenge. Liposomal encapsulation of antisense oligonucleotides protects them from degradation and enhances drug delivery. Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.